Aligos Therapeutics (ALGS) AI Stock Analysis

496 Followers

Aligos Therapeutics

(NASDAQ:ALGS)

Select Model

Rating:41Neutral

Price Target:$4.50▼(-10.36% Downside)

Action:reiterated

Date:09/13/26

ALGS scores low primarily due to weak financial performance (persistent losses, declining revenue, and heavy ongoing cash burn) and bearish technical trends (price below key moving averages with negative MACD). Corporate governance actions provide only modest support, while valuation is constrained by negative earnings and no dividend data.

Positive Factors

High Gross MarginThe reported gross margin indicates that ALGS’s revenue carries strong economics before operating expenses. If the company can expand programs or commercialize candidates, this margin profile could provide meaningful operating leverage, although current revenue remains too small to cover its cost base.

Negative Factors

Persistent UnprofitabilityPersistent operating and net losses show that ALGS’s current revenue base does not support its expense structure. Unless development activity produces substantially greater revenue or operating costs decline, ongoing deficits will continue to weaken retained capital and limit internally funded investment.

Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $31.35M
Dividend Yield: ―
Average Volume (3M): 68.81K
Price to Earnings (P/E): -0.7
Beta (1Y): 1.61
Revenue Growth: 893.01%
EPS Growth: 41.74%
Country: US
Employees: 82
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antige...

Aligos Therapeutics Financial Statement Overview

Summary

Overall fundamentals are weak: the company shows persistent, large operating and net losses, shrinking TTM revenue (~-20.5% YoY), and materially negative TTM operating/free cash flow (about -$94M/-$95M). Positives include very high TTM gross margin (~89%) and modest leverage (TTM debt-to-equity ~0.14), but balance-sheet fragility (equity was negative in 2024) and ongoing cash burn keep the financial profile low-scoring.

Income Statement

18Very Negative

Balance Sheet

55Neutral

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	31.52M	2.19M	3.94M	15.53M	13.91M	4.36M
Gross Profit	31.26M	1.26M	3.94M	15.53M	13.91M	4.36M
EBITDA	-70.70M	-22.95M	-128.26M	-83.81M	-92.27M	-124.41M
Net Income	-75.96M	-24.19M	-131.21M	-87.68M	-96.05M	-128.33M
Balance Sheet
Total Assets	66.33M	88.53M	70.09M	151.53M	146.69M	235.37M
Cash, Cash Equivalents and Short-Term Investments	30.38M	77.84M	56.94M	135.70M	125.83M	190.73M
Total Debt	3.50M	5.25M	8.38M	11.14M	12.57M	14.46M
Total Liabilities	34.44M	34.99M	99.07M	59.45M	42.79M	50.64M
Stockholders Equity	31.88M	53.55M	-28.97M	92.08M	103.90M	184.73M
Cash Flow
Free Cash Flow	-94.52M	-82.94M	-80.87M	-79.02M	-80.33M	-116.55M
Operating Cash Flow	-94.17M	-82.50M	-80.74M	-79.00M	-79.39M	-115.66M
Investing Cash Flow	105.59M	-37.83M	-18.28M	44.98M	-26.29M	3.02M
Financing Cash Flow	228.00K	101.64M	355.00K	88.33M	164.00K	78.68M

Aligos Therapeutics Technical Analysis

Technical Analysis SentimentNeutral

Last Price5.02

Price Trends

50DMA5.43Negative

100DMA5.58Negative

200DMA6.19Negative

Market Momentum

MACD-0.17Negative

RSI48.31Neutral

STOCH29.09Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Neutral. The current price of 5.02 is above the 20-day moving average (MA) of 5.02, below the 50-day MA of 5.43, and below the 200-day MA of 6.19, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 48.31 is Neutral, neither overbought nor oversold. The STOCH value of 29.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALGS.

Aligos Therapeutics Risk Analysis

Aligos Therapeutics disclosed 91 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Aligos Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ALGS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACRV	59Neutral	$71.57M	-0.93	-70.14%	―	―	16.04%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CELU	44Neutral	$26.52M	-0.45	142.25%	―	-58.14%	47.25%
ALGS	41Neutral	$29.66M	-0.69	-160.72%	―	893.01%	41.74%

* Healthcare Sector Average

Performance Comparison

ALGS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ALGS	Aligos Therapeutics, Inc.	5.02	-2.08	-29.30%
MNOV	Medicinova	1.45	0.05	3.57%
CELU	Celularity Inc.	0.81	-0.88	-52.19%
GNTA	Genenta Science SpA Sponsored ADR	0.70	-1.59	-69.43%
ACRV	Acrivon Therapeutics, Inc.	1.74	-0.26	-13.00%

Aligos Therapeutics Corporate Events

Business Operations and Strategy

Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

Neutral

Sep 15, 2026

On September 10, 2026, Aligos Therapeutics, Inc. amended its headquarters lease with Britannia Biotech Gateway Limited Partnership, extending the term for its South San Francisco office space from March 31, 2027 to March 31, 2034. The agreement sets...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 13, 2026

Aligos Therapeutics AI Stock Analysis